Invivyd Inc. (IVVD) - Total Liabilities
Based on the latest financial reports, Invivyd Inc. (IVVD) has total liabilities worth $35.34 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IVVD cash flow conversion to assess how effectively this company generates cash.
Invivyd Inc. - Total Liabilities Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check IVVD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Invivyd Inc. Competitors by Total Liabilities
The table below lists competitors of Invivyd Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Corem Property Group AB (publ)
ST:CORE-B
|
Sweden | Skr36.64 Billion |
|
China Resources Medical Holdings Company Limited
F:1PH
|
Germany | €5.82 Billion |
|
Grand Pacific Petrochemical Corp
TW:1312
|
Taiwan | NT$30.11 Billion |
|
Okea ASA
OL:OKEA
|
Norway | Nkr1.76 Billion |
|
Grieg Seafood ASA
OL:GSF
|
Norway | Nkr7.73 Billion |
|
Seah Holdings
KO:058650
|
Korea | ₩3.31 Trillion |
|
Yarward Electronics Shandong Co. Ltd. A
SHE:301337
|
China | CN¥142.23 Million |
|
TWC Enterprises Ltd
TO:TWC
|
Canada | CA$109.59 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down Invivyd Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Invivyd Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.24 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Invivyd Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Invivyd Inc. (2020–2025)
The table below shows the annual total liabilities of Invivyd Inc. from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $35.34 Million | -42.97% |
| 2024-12-31 | $61.98 Million | +19.85% |
| 2023-12-31 | $51.71 Million | +90.14% |
| 2022-12-31 | $27.20 Million | -56.18% |
| 2021-12-31 | $62.07 Million | -66.01% |
| 2020-12-31 | $182.63 Million | -- |
About Invivyd Inc.
Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's pipeline includes PEMGARDA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate, which i… Read more